Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:CADL NASDAQ:IPHA NASDAQ:OCS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$5.29+5.4%$4.57$1.38▼$5.35$701.11M0.761.81 million shs3.19 million shsCADLCandel Therapeutics$10.30-0.6%$8.19$4.35▼$11.36$759.08M-0.492.13 million shs2.94 million shsIPHAInnate Pharma$1.84+2.2%$1.71$1.17▼$2.63$169.06M0.3137,304 shs9,900 shsOCSOculis$13.87+6.0%$21.34$10.52▼$34.47$759.01M0.23869,783 shs633,549 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+0.40%+3.72%+10.33%+33.87%+241.50%CADLCandel Therapeutics+5.82%+13.22%+24.82%+110.78%+111.43%IPHAInnate Pharma+0.56%-0.55%-1.64%+40.63%-2.70%OCSOculis+9.08%+12.17%-42.34%-50.77%-32.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$5.29+5.4%$4.57$1.38▼$5.35$701.11M0.761.81 million shs3.19 million shsCADLCandel Therapeutics$10.30-0.6%$8.19$4.35▼$11.36$759.08M-0.492.13 million shs2.94 million shsIPHAInnate Pharma$1.84+2.2%$1.71$1.17▼$2.63$169.06M0.3137,304 shs9,900 shsOCSOculis$13.87+6.0%$21.34$10.52▼$34.47$759.01M0.23869,783 shs633,549 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+0.40%+3.72%+10.33%+33.87%+241.50%CADLCandel Therapeutics+5.82%+13.22%+24.82%+110.78%+111.43%IPHAInnate Pharma+0.56%-0.55%-1.64%+40.63%-2.70%OCSOculis+9.08%+12.17%-42.34%-50.77%-32.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$11.50117.39% UpsideCADLCandel Therapeutics 2.56Moderate Buy$18.0074.76% UpsideIPHAInnate Pharma 2.50Moderate Buy$5.00171.74% UpsideOCSOculis 2.80Moderate Buy$38.33176.38% UpsideCurrent Analyst Ratings BreakdownLatest IPHA, OCS, ACRS, and CADL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026ACRSAclaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/11/2026OCSOculis HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/3/2026OCSOculis JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$42.00 ➝ $23.006/2/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$13.006/1/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/1/2026OCSOculis Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$49.00 ➝ $38.006/1/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/1/2026OCSOculis Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.006/1/2026OCSOculis GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$75.00 ➝ $45.006/1/2026OCSOculis HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$47.00 ➝ $26.00(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$7.83M94.36N/AN/A$0.85 per share6.22CADLCandel TherapeuticsN/AN/AN/AN/A$0.95 per shareN/AIPHAInnate Pharma$2.79M62.01N/AN/A($0.26) per share-7.08OCSOculis$1.45M554.61N/AN/A$4.08 per share3.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%8/6/2026 (Estimated)CADLCandel Therapeutics-$38.18M-$0.98N/AN/AN/AN/A-60.42%-41.33%8/13/2026 (Estimated)IPHAInnate Pharma-$55.64MN/AN/AN/AN/AN/AN/AN/A9/17/2026 (Estimated)OCSOculis-$119.44M-$2.13N/AN/AN/A-8,460.67%-56.78%-45.62%8/6/2026 (Estimated)Latest IPHA, OCS, ACRS, and CADL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CADLCandel Therapeutics-$0.2958-$0.14+$0.1558-$0.14N/AN/A5/8/2026Q1 2026OCSOculis-$0.49-$0.63-$0.14-$0.61$0.25 million$0.26 million5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03CADLCandel Therapeutics0.3428.0528.05IPHAInnate PharmaN/A1.271.27OCSOculis0.015.185.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%CADLCandel Therapeutics13.93%IPHAInnate Pharma0.16%OCSOculis22.30%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics4.80%CADLCandel Therapeutics14.30%IPHAInnate Pharma31.89%OCSOculisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million132.96 millionOptionableCADLCandel Therapeutics6073.27 million62.79 millionOptionableIPHAInnate Pharma22093.92 million63.97 millionNot OptionableOCSOculis257.98 millionN/ANot OptionableIPHA, OCS, ACRS, and CADL HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCSJune 25, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCSJune 23, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCSJune 18, 2026 | prnewswire.comOCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law FirmJune 17, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCSJune 16, 2026 | globenewswire.comOCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law FirmJune 11, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCSJune 11, 2026 | prnewswire.comOculis Holding AG to Present Privosegtor Development at Clinical Trials at the Summit 2026June 11, 2026 | quiverquant.comQOculis Holding AG to Present on Privosegtor at Clinical Trials at the Summit 2026June 11, 2026 | quiverquant.comQOculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026June 11, 2026 | globenewswire.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesJune 10, 2026 | globenewswire.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesJune 9, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCSJune 9, 2026 | globenewswire.comOculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye DiseaseJune 9, 2026 | globenewswire.comNan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug StumblesJune 8, 2026 | aol.comAOculis Holding AG to Provide Update on Late-Stage Portfolio at 47th Annual Goldman Sachs Global Healthcare ConferenceJune 8, 2026 | quiverquant.comQOculis to Present at the 47th Annual Goldman Sachs Global Healthcare ConferenceJune 8, 2026 | globenewswire.comOCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law FirmJune 8, 2026 | prnewswire.comOculis Holding AG (OCS) Securities Fraud Investigation - Levi & KorsinskyJune 8, 2026 | prnewswire.comLost Money on Oculis Holding AG (OCS)? Contact Levi & Korsinsky About InvestigationJune 7, 2026 | newsfilecorp.comNOculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision GoalsMay 31, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 20263 Penny Stocks Under $5 Backed by Real Revenue GrowthBy Chris Markoch | June 20, 2026IPHA, OCS, ACRS, and CADL Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$5.29 +0.27 (+5.38%) Closing price 04:00 PM EasternExtended Trading$5.68 +0.39 (+7.45%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Candel Therapeutics NASDAQ:CADL$10.30 -0.06 (-0.58%) Closing price 04:00 PM EasternExtended Trading$10.55 +0.25 (+2.43%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Innate Pharma NASDAQ:IPHA$1.84 +0.04 (+2.22%) Closing price 04:00 PM EasternExtended Trading$1.84 0.00 (-0.05%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Oculis NASDAQ:OCS$13.87 +0.78 (+5.96%) Closing price 04:00 PM EasternExtended Trading$13.88 +0.01 (+0.04%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
